



**FIGURE 1**




	PATIENTS RECEIVING		
	2.5 MG	5 MG	10 MG
● NALBUPHINE ALONE	31	33	30
▼ + NALOXONE 0.4 MG	30	30	26
■ NALOXONE 0.4 MG ALONE	28	28	28

**d** Nalbuphine 2.5, 5, 10 mg + Naloxone 0.4 mg  
Males / Females Combined




**FIGURE 2**

Males/females combined




● nalbuphine alone	2.5 mg	5mg	10 mg
▼ + naloxone 0.4 mg	26	33	30
■ naloxone 0.4 mg alone	27	30	25
	28	28	28

**d Nalbuphine 2.5, 5, 10 mg + naloxone 0.4 mg**




**FIGURE 3**

Naibupnine 5 mg + naloxone 0.1, 0.2 & 0.4 mg




**FIGURE 4**




**FIGURE 5**

Nalbuphine 2.5 mg alone and + naloxone 0.2 mg  
(males co-varied for baseline pain)




**FIGURE 6**




Pre- and 60 Minutes Post-drug Administration

**FIGURE 7**



Pre- and 60 Minutes Post-drug Administration


**FIGURE 8**



Pre- and 60 Minutes Post-drug Administration




**FIGURE 9**



**FIGURE 10**

**Nerve Injury Study  
(Nalbuphine 5 mg + Naloxone 0.4 mg)**



**FIGURE 11**

# **Intra-nasal nalbuphine-naloxone combination**

